Company News

Term: Company News

  • 10/23/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present seven posters detailing findings from clinical studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) as well as from the Global aHUS Registry at the annual meeting of the American Society of Nephrology (ASN), being held November 11-16, 2014, in Philadelphia. aHUS is a genetic, chronic, ultra-rare disease associated withmore...
  • 10/15/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that it has submitted a New Drug Application (NDA) for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia (HPP), to Japan’s Ministry of Health, Labour and Welfare (MHLW). HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound musclemore...
  • 10/9/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2014 on Thursday, October 23, 2014 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast on Thursday, October 23, 2014, at 10:00 a.m. Eastern Time (ET). To participate in this conferencemore...
  • 10/9/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--The Board of Directors of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Leonard Bell, M.D. has been appointed Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as Chief Executive Officer of the Company. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby, who was voted Lead Independent Director by the othermore...
  • 10/7/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Max Link, Ph.D., Chairman of the Board of Directors of Alexion, passed away unexpectedly on October 5 while traveling on business. Dr. Link, a globally respected leader of companies in the pharmaceutical, biotechnology and medical device industries over the course of nearly four decades, served as a Director of Alexion since the Company was established in April 1992 and assumed themore...
  • 9/17/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced key measures to strengthen and broaden its executive leadership team in line with the Company’s expanding global mission to develop and commercialize life-transforming therapies for patients with severe and rare disorders. David Hallal is being promoted to the newly created position of Chief Operating Officer and has been appointed to Alexion’s Board of Directors. Mr. Hallalmore...
  • 9/3/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the National Institute for Health and Clinical Excellence (NICE) Highly Specialised Technologies Evaluation Committee (EC) has reaffirmed the very significant clinical value of eculizumab (Soliris®) for the treatment of atypical hemolytic uremic syndrome (aHUS) and the lack of other effective therapies, and has issued a recommendation that it be nationally commissioned for allmore...
  • 8/28/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Robert W. Baird & Co. 2014 Health Care Conference in New York City on Thursday, September 4th at 12:15 p.m., Eastern Time Morgan Stanley 2014 Global Healthcare Unplugged Conference in New York City on Monday, September 8th at 1:25 p.m., Eastern Time An audio webcast of each presentation will bemore...
  • 7/16/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to the Company’s Board of Directors, effective immediately. With the appointments announced today, 10 of Alexion's 11 directors are independent. “David, Michele and Chris bring significant commercial, financial, risk management and operational expertise to the Board, and, following on themore...
  • 7/10/14
    CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2014 on Thursday, July 24, 2014 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast on Thursday, July 24, 2014, at 10:00 a.m. Eastern Time (ET). To participate in this conference call, dialmore...